Literature DB >> 9005967

Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation.

R J Keogh1, M E Dunlop, R G Larkins.   

Abstract

Activation of the polyol pathway under hyperglycemic conditions is proposed to contribute to the development of diabetic nephropathy. The mechanisms by which this activation may lead to functional and structural changes within the kidney are yet to be definitively established. We have examined in vitro the steps linking increased polyol pathway activity resulting from hyperglycemia to prostaglandin production. Following the demonstration of increased prostaglandin E (PGE) levels in glomeruli from diabetic rats (14.9 +/- 2.5 v 59.1 +/- 19.4 ng PGE/mg protein), a specific inhibitor of aldose reductase, HOE-843, was used in vitro to analyze the response to hyperglycemia of the steps preceding prostaglandin production. In explants of glomeruli from control animals, increasing the glucose concentration in vitro from 5.6 mmol/L to 25 mmol/L resulted in a significant increase in the flux of glucose through the pentose phosphate pathway ([PPP] 1.29 +/- 0.08 v 2.00 +/- 0.11 nmol/h), de novo diacylglycerol synthesis (2.2 +/- 0.1 v 3.1 +/- 0.2 micromol/mg protein), membrane protein kinase C (PKC) activity (18.7 +/- 0.5 v 24.3 +/- 0.75 pmol/microg protein), and in vitro phospholipase A2 (PLA2) activity (2.18 +/- 0.46 v 3.83 +/- 1.07 nmol arachidonic acid hydrolyzed/min/mg cytosolic protein). For all parameters measured, the increase resulting from the increased glucose concentration could be prevented by in vitro addition of HOE-843 for 24 hours before measurement. These findings provide evidence to suggest a mechanism linking increased polyol pathway activity and an increase in PLA2 activity to increased prostaglandin production, which is observed in diabetes of recent onset and may ultimately lead to changes associated with the development of diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9005967     DOI: 10.1016/s0026-0495(97)90165-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  11 in total

Review 1.  Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy.

Authors:  G Pugliese; F Pricci; G Romeo; G Leto; L Amadio; C Iacobini; U Di Mario
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy.

Authors:  F Lang; K Klingel; C A Wagner; C Stegen; S Warntges; B Friedrich; M Lanzendorfer; J Melzig; I Moschen; S Steuer; S Waldegger; M Sauter; M Paulmichl; V Gerke; T Risler; G Gamba; G Capasso; R Kandolf; S C Hebert; S G Massry; S Broër
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Aldose reductase inhibition counteracts nitrosative stress and poly(ADP-ribose) polymerase activation in diabetic rat kidney and high-glucose-exposed human mesangial cells.

Authors:  Viktor R Drel; Pal Pacher; Martin J Stevens; Irina G Obrosova
Journal:  Free Radic Biol Med       Date:  2006-01-31       Impact factor: 7.376

Review 4.  Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation.

Authors:  Hamdy Nassar; Alpdogan Kantarci; Thomas E van Dyke
Journal:  Periodontol 2000       Date:  2007       Impact factor: 7.589

5.  Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.

Authors:  Irina G Obrosova; Pal Pacher; Csaba Szabó; Zsuzsanna Zsengeller; Hiroko Hirooka; Martin J Stevens; Mark A Yorek
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

Review 6.  Dietary hyperglycemia, glycemic index and metabolic retinal diseases.

Authors:  Chung-Jung Chiu; Allen Taylor
Journal:  Prog Retin Eye Res       Date:  2010-09-22       Impact factor: 21.198

Review 7.  Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.

Authors:  Ravichandran Ramasamy; Ira J Goldberg
Journal:  Circ Res       Date:  2010-05-14       Impact factor: 17.367

8.  Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats.

Authors:  Joong Kyung Sung; Jang Hyun Koh; Mi Young Lee; Bo Hwan Kim; Soo Min Nam; Jae Hyun Kim; Jin Hee Yoo; So Hee Kim; Sun Won Hong; Eun Young Lee; Ran Choi; Choon Hee Chung
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

9.  Genetic deficiency of aldose reductase counteracts the development of diabetic nephropathy in C57BL/6 mice.

Authors:  H Liu; Y Luo; T Zhang; Y Zhang; Q Wu; L Yuan; S S M Chung; P J Oates; J Y Yang
Journal:  Diabetologia       Date:  2011-01-27       Impact factor: 10.122

10.  Renoprotective Effects of Aldose Reductase Inhibitor Epalrestat against High Glucose-Induced Cellular Injury.

Authors:  Heba El Gamal; Ali Hussein Eid; Shankar Munusamy
Journal:  Biomed Res Int       Date:  2017-03-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.